Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPIRINOX adjuvant chemotherapy trial in resected ampullary adenocarcinoma
2024-511070-68-01Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, irinotecan, folinic acid, fluorouracil, capecitabine and 1 more in ampullary adenocarcinoma (3 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disease-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
oxaliplatinirinotecanfolinic acidfluorouracilcapecitabine
03
Conditions
ampullary adenocarcinoma
Beyond the preview
Go deeper on 2024-511070-68-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511070-68-01.